CA2989644A1 - Method for improving health outcomes - Google Patents
Method for improving health outcomes Download PDFInfo
- Publication number
- CA2989644A1 CA2989644A1 CA2989644A CA2989644A CA2989644A1 CA 2989644 A1 CA2989644 A1 CA 2989644A1 CA 2989644 A CA2989644 A CA 2989644A CA 2989644 A CA2989644 A CA 2989644A CA 2989644 A1 CA2989644 A1 CA 2989644A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- skin
- cloth
- wiping
- tissues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 102
- 230000036541 health Effects 0.000 title claims abstract description 67
- 210000001519 tissue Anatomy 0.000 claims abstract description 79
- 210000003205 muscle Anatomy 0.000 claims abstract description 53
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 40
- 210000003491 skin Anatomy 0.000 claims description 159
- 239000000203 mixture Substances 0.000 claims description 97
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 76
- 208000015181 infectious disease Diseases 0.000 claims description 61
- 210000000434 stratum corneum Anatomy 0.000 claims description 37
- 239000004744 fabric Substances 0.000 claims description 36
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 28
- 239000004615 ingredient Substances 0.000 claims description 25
- 210000002640 perineum Anatomy 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 230000001737 promoting effect Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 230000002378 acidificating effect Effects 0.000 claims description 18
- 235000011399 aloe vera Nutrition 0.000 claims description 18
- 210000004400 mucous membrane Anatomy 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 14
- 229960000458 allantoin Drugs 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 239000003974 emollient agent Substances 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 14
- 239000003906 humectant Substances 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 12
- 229920002498 Beta-glucan Polymers 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 12
- 238000006213 oxygenation reaction Methods 0.000 claims description 12
- 210000002700 urine Anatomy 0.000 claims description 12
- 239000002699 waste material Substances 0.000 claims description 12
- 206010021639 Incontinence Diseases 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 210000002683 foot Anatomy 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 244000144927 Aloe barbadensis Species 0.000 claims description 10
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 10
- 230000010261 cell growth Effects 0.000 claims description 10
- 230000001010 compromised effect Effects 0.000 claims description 10
- 206010049816 Muscle tightness Diseases 0.000 claims description 9
- 210000002414 leg Anatomy 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 210000001099 axilla Anatomy 0.000 claims description 7
- 238000011109 contamination Methods 0.000 claims description 7
- 239000006260 foam Substances 0.000 claims description 7
- 230000007760 free radical scavenging Effects 0.000 claims description 7
- 230000002503 metabolic effect Effects 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 208000007101 Muscle Cramp Diseases 0.000 claims description 6
- 210000001217 buttock Anatomy 0.000 claims description 6
- 230000036512 infertility Effects 0.000 claims description 6
- 230000033001 locomotion Effects 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002516 radical scavenger Substances 0.000 claims description 5
- 230000002000 scavenging effect Effects 0.000 claims description 5
- 240000000560 Citrus x paradisi Species 0.000 claims description 4
- 239000002518 antifoaming agent Substances 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 230000001937 non-anti-biotic effect Effects 0.000 claims description 4
- 206010000591 Acrochordon Diseases 0.000 claims description 3
- 235000002532 grape seed extract Nutrition 0.000 claims description 3
- 229940087603 grape seed extract Drugs 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 235000018192 pine bark supplement Nutrition 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 229940106796 pycnogenol Drugs 0.000 claims description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical group O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 2
- 206010050031 Muscle strain Diseases 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 abstract description 41
- 230000006378 damage Effects 0.000 abstract description 39
- 238000012423 maintenance Methods 0.000 abstract description 33
- 230000004888 barrier function Effects 0.000 abstract description 30
- 230000006870 function Effects 0.000 abstract description 28
- 230000000737 periodic effect Effects 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
- 208000027418 Wounds and injury Diseases 0.000 abstract description 22
- 230000000699 topical effect Effects 0.000 abstract description 9
- 208000014674 injury Diseases 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 6
- 230000003938 response to stress Effects 0.000 abstract description 4
- 206010029803 Nosocomial infection Diseases 0.000 abstract description 3
- 230000003950 pathogenic mechanism Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 142
- 229940111068 theraworx Drugs 0.000 description 59
- 239000000047 product Substances 0.000 description 35
- 241000894006 Bacteria Species 0.000 description 22
- 238000003780 insertion Methods 0.000 description 20
- 230000037431 insertion Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 241000700605 Viruses Species 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 230000035699 permeability Effects 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 15
- 238000010586 diagram Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 230000035876 healing Effects 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000002485 urinary effect Effects 0.000 description 12
- 244000005700 microbiome Species 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 11
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 208000002874 Acne Vulgaris Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010000496 acne Diseases 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229940008099 dimethicone Drugs 0.000 description 9
- 239000004205 dimethyl polysiloxane Substances 0.000 description 9
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 9
- 210000000214 mouth Anatomy 0.000 description 9
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000036572 transepidermal water loss Effects 0.000 description 9
- 241001116389 Aloe Species 0.000 description 8
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000000386 athletic effect Effects 0.000 description 8
- 229960003260 chlorhexidine Drugs 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 208000019206 urinary tract infection Diseases 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 206010040844 Skin exfoliation Diseases 0.000 description 6
- 230000001332 colony forming effect Effects 0.000 description 6
- 230000002498 deadly effect Effects 0.000 description 6
- 230000007123 defense Effects 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000008093 supporting effect Effects 0.000 description 6
- 241001115402 Ebolavirus Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000037147 athletic performance Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 230000035618 desquamation Effects 0.000 description 5
- 210000000613 ear canal Anatomy 0.000 description 5
- 229940065115 grapefruit extract Drugs 0.000 description 5
- 210000004013 groin Anatomy 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 230000000474 nursing effect Effects 0.000 description 5
- 230000008092 positive effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000011012 sanitization Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 206010006803 Burns third degree Diseases 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 206010042496 Sunburn Diseases 0.000 description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940064004 antiseptic throat preparations Drugs 0.000 description 4
- 210000000617 arm Anatomy 0.000 description 4
- 238000003287 bathing Methods 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000000736 corneocyte Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000036074 healthy skin Effects 0.000 description 4
- 230000003116 impacting effect Effects 0.000 description 4
- 210000001613 integumentary system Anatomy 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000010740 swine influenza Diseases 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229960003500 triclosan Drugs 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010006797 Burns first degree Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- -1 grapefruit extract Chemical compound 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 208000037801 influenza A (H1N1) Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000011418 maintenance treatment Methods 0.000 description 3
- 230000005541 medical transmission Effects 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000014599 transmission of virus Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010006802 Burns second degree Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000034347 Faecal incontinence Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 240000007049 Juglans regia Species 0.000 description 2
- 235000009496 Juglans regia Nutrition 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 201000010618 Tinea cruris Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940070021 anabolic steroids Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003254 anti-foaming effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 229940047652 ear drops Drugs 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 2
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 2
- 229940048848 lauryl glucoside Drugs 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000012449 sabouraud dextrose agar Substances 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 210000005010 torso Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001331781 Aspergillus brasiliensis Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010073024 Preterm premature rupture of membranes Diseases 0.000 description 1
- 208000001818 Pseudofolliculitis barbae Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 238000003070 Statistical process control Methods 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 241001115400 Zaire ebolavirus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000013056 hazardous product Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 208000011354 prosthesis-related infectious disease Diseases 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 231100000735 select agent Toxicity 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 231100000933 sensitization response Toxicity 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/745,091 | 2015-06-19 | ||
| US14/745,091 US20160158393A1 (en) | 2014-02-21 | 2015-06-19 | Method for Improving Health Outcomes |
| PCT/US2016/038043 WO2016205620A1 (en) | 2015-06-19 | 2016-06-17 | Method for improving health outcomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2989644A1 true CA2989644A1 (en) | 2016-12-22 |
Family
ID=56464282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2989644A Pending CA2989644A1 (en) | 2015-06-19 | 2016-06-17 | Method for improving health outcomes |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3310443A1 (pt) |
| JP (1) | JP2018521992A (pt) |
| BR (1) | BR112017027349B1 (pt) |
| CA (1) | CA2989644A1 (pt) |
| MX (2) | MX2017016911A (pt) |
| WO (2) | WO2016205620A1 (pt) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107693457A (zh) * | 2017-11-16 | 2018-02-16 | 东兴市良佳优农林科技有限公司 | 止痒洗发露 |
| CN107737070A (zh) * | 2017-11-16 | 2018-02-27 | 东兴市良佳优农林科技有限公司 | 杀菌、护肤洗手液 |
| US11925768B2 (en) | 2014-02-21 | 2024-03-12 | Avadim Health Ip, Inc. | Method for decolonizing mammalian skin |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021155362A (ja) * | 2020-03-27 | 2021-10-07 | 株式会社ナリス化粧品 | ペルオキシナイトライト活性阻害方法および、ペルオキシナイトライト活性阻害剤のスクリーニング方法 |
| IT202000021634A1 (it) * | 2020-09-16 | 2020-12-16 | Prete Antonio Del | Dispositivo per la somministrazione di una soluzione con iodiopovidone per la prevenzione delle infezioni dell'occhio |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0748242A4 (en) * | 1994-02-28 | 1998-11-18 | Incline Technologies Inc | METHOD AND SYSTEM FOR CLEANING THE SKIN |
| US6358516B1 (en) | 1998-08-21 | 2002-03-19 | Norris R. Harod | One-step system for cleansing, conditioning, and treating the skin |
| US9814737B2 (en) * | 2010-04-27 | 2017-11-14 | Mercy Medical Research Institute | Composition for skin sanitization and protection and method of its use |
| US9327029B2 (en) * | 2011-05-05 | 2016-05-03 | Celacare Technologies, Llc | Antimicrobial silver hydrogel composition for the treatment of burns and wounds |
-
2016
- 2016-06-17 BR BR112017027349-7A patent/BR112017027349B1/pt active IP Right Grant
- 2016-06-17 CA CA2989644A patent/CA2989644A1/en active Pending
- 2016-06-17 WO PCT/US2016/038043 patent/WO2016205620A1/en active Application Filing
- 2016-06-17 MX MX2017016911A patent/MX2017016911A/es unknown
- 2016-06-17 EP EP16741722.9A patent/EP3310443A1/en active Pending
- 2016-06-17 JP JP2017565934A patent/JP2018521992A/ja active Pending
- 2016-06-20 WO PCT/US2016/038409 patent/WO2016205812A1/en active Application Filing
-
2017
- 2017-12-19 MX MX2022005561A patent/MX2022005561A/es unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11925768B2 (en) | 2014-02-21 | 2024-03-12 | Avadim Health Ip, Inc. | Method for decolonizing mammalian skin |
| CN107693457A (zh) * | 2017-11-16 | 2018-02-16 | 东兴市良佳优农林科技有限公司 | 止痒洗发露 |
| CN107737070A (zh) * | 2017-11-16 | 2018-02-27 | 东兴市良佳优农林科技有限公司 | 杀菌、护肤洗手液 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016205620A1 (en) | 2016-12-22 |
| MX2017016911A (es) | 2019-06-24 |
| WO2016205812A1 (en) | 2016-12-22 |
| JP2018521992A (ja) | 2018-08-09 |
| MX2022005561A (es) | 2022-07-21 |
| BR112017027349A2 (pt) | 2018-08-21 |
| BR112017027349B1 (pt) | 2021-07-06 |
| EP3310443A1 (en) | 2018-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11925768B2 (en) | Method for decolonizing mammalian skin | |
| US20200306394A1 (en) | Methods for improving integumentary tissue by topically applying acidifying compositions | |
| KR102108109B1 (ko) | 국소 소독 제제 및 이의 용도 | |
| CA2562329C (en) | Therapeutic antimicrobial compositions and methods | |
| CA2989644A1 (en) | Method for improving health outcomes | |
| EP2563356A2 (en) | A composition for skin sanitization and protection and method of its use | |
| US7012096B2 (en) | Composition for pain mediation and apparatus and method of use thereof | |
| Alhouri et al. | Possible side effects of using detergents during the Covid19 pandemic in Syria | |
| Graça et al. | Indirect consequences of coronavirus disease 2019: Skin lesions caused by the frequent hand sanitation and use of personal protective equipment and strategies for their prevention | |
| CA2532555A1 (en) | Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil | |
| CN105687021A (zh) | 防治脚癣的爽足粉 | |
| Marriott et al. | Personal hygiene and sanitary food handling | |
| Davis | Effectiveness of CHG Bathing | |
| CN104435606A (zh) | 一种中草药皮肤消毒剂 | |
| CN102008502B (zh) | 肤康液 | |
| Ziady | Infection prevention and control: reviewing soap and detergents for procurement by healthcare facilities: infection control |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |
|
| EEER | Examination request |
Effective date: 20210617 |